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Hepatitis C virus (HCV) Core protein is implicated in the development of hepatocellular carcinoma (HCC). We utilized a HepG2 human
hepatocyte cell line with inducible expression of HCV Core protein (HCV-1b) to investigate the early effects of Core protein on hepatocyte gene
expression and to identify molecular processes modulated by the Core protein. A significant change was observed in the expression of 407 genes,
which included genes regulating apoptosis, immune response, and cell cycle. Some of these genes were previously known to be tumor markers.
The decreased expression of chemo-attractants such as TNFSF10, CCL20, and osteopontin was observed, which suggested that HCV Core
expression could lead to suppression of inflammatory response as well as trafficking of macrophages and neutrophils to the site of HCV infection.
An increased expression of anti-apoptosis factors including PAK2, API5, BH1, Tax1BP1, DAXX, and TNFAIP3/A20 was observed. Some of
these genes were also linked to the regulation of NFKB activation and that the alteration of their expression levels, by HCV Core, might lead to the
suppression NFKB activation of inflammatory responses. Our data suggested that Core expression may contribute to the viral persistence by
protecting infected hepatocytes from cell death by the suppressing apoptosis and inflammatory reaction to HCV viral infection.
© 2006 Elsevier Inc. All rights reserved.Keywords: HCV Core; Immune regulation; Apoptosis; MicroarrayIntroduction
Hepatitis C virus (HCV) is the etiologic agent of acute and
chronic hepatitis affecting more than 100 million people
worldwide (Uchida, 1994). Chronic hepatitis is one of the
leading causes of liver cirrhosis and hepatocellular carcinoma
(HCC) (Saito et al., 1990), yet the mechanisms of viral
persistence and HCV associated tumorigenesis have not been
fully elucidated. HCV, a member of the flavivirus family, has a
9.5-kb positive single-stranded RNA genome, which encodes a
polyprotein that is processed into at least 10 different structural
and nonstructural proteins (Choo et al., 1989; Ray and Ray,
2001). The HCV Core protein is derived from the N-terminus of
the polypeptide and has a highly basic N-terminal region and a
highly hydrophobic C-terminus (Kunkel and Watowich, 2002).
In addition to being the major component of the viral⁎ Corresponding author. Fax: +1 530 752 8692.
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doi:10.1016/j.virol.2006.04.028nucleocapsid, this multifunctional protein has also been
implicated in hepatocyte proliferation and cellular transforma-
tion, although molecular mechanisms mediating these processes
are not fully determined.
Several human and murine studies have investigated
mechanisms of HCV Core protein in the development of
HCC which included the effects on the cell cycle and growth.
We reported that the expression of HCV Core protein
modulated cell cycle of hepatocytes as indicated by an increased
level of the cell-cycle-dependent kinase inhibitor (CdkI) p21, a
target of the p53 tumor suppressor, and found that the increased
level of p21 corresponded to a decreased level of cdk2 kinase
activity and arrested HepG2 hepatocytes in the G0/G1 phase of
the cell cycle (Nguyen et al., 2003). The CdkI p21 has a
dominant role in arresting cells in the G0/G1 phase of the cell
cycle by inhibiting the kinase activity of Cdk2-cyclin E
complex. Other studies have also demonstrated that HCV
Core protein modulates the expression of p21 (Oka et al., 2003;
Yamanaka et al., 2002). It has been reported that the p53 tumor
Fig. 1. (A) Expression of HCV Core protein in hepatocytes. Western blot
analysis demonstrates the inducible expression of HCV Core protein in HepG2-
Core cells. Induced (I) and uninduced (UI) in triplicates. The numbers in the
parentheses indicate the individual experiment subsets of the triplicate
experiment. (B) Expression of HCV Core protein in HepG2-Core cells reduced
cell proliferation. The Core expression in HepG2-Core cells was induced with
PonA for 48 h and compared to uninduced HepG2-Core cells. Live cells were
counted with Trypan blue dye. Nontransfected HepG2 cells with and without
PonA induction served as negative control for cell proliferation assay. Each cell
growth assay was performed in triplicates.
59H. Nguyen et al. / Virology 354 (2006) 58–68suppressor is activated in the presence of HCV Core protein
expression (Lu et al., 1999) which could lead to an increased
expression of p21. Cyclin E, a protein instrumental in the
transversal of the G1/S checkpoint, was shown to be elevated in
cells expressing HCV Core protein (Cho et al., 2001). In
addition, Core protein activates the c-myc promoter but
suppresses the fos promoter, indicating that HCV Core is a
potential regulator of oncogenes (Ray et al., 1995). In our
previous studies, we observed that HepG2 cells with HCV Core
expression accumulated in the G0/G1 phase of the cell cycle
(Nguyen et al., 2003). Other studies of HCV Core protein
expression using the Huh-7 cell line reported either enhanced or
no change in cell proliferation (Fukutomi et al., 2005; Li et al.,
2002). The Huh7 cell line contains a point mutation of the p53
gene, while the HepG2 cell line has the wt p53 gene copies,
which could lead to different effects of Core protein on cell
proliferation. However, these studies together suggest that Core
protein may have an impact on HCV pathogenesis through
modulation of cell cycle regulatory mechanisms.
HCV Core protein is also linked to the formation of steatosis
both in in vitro cell cultures and in vivo. Core protein expression
increased the formation of cellular lipid droplets, and Core co-
localized with apolipoprotein AII on the surface of cytoplasmic
lipid droplets (Barba et al., 1997; Sabile et al., 1999). Expression
of Core protein in the liver of transgenic mice induced hepatic
steatosis (Moriya et al., 1997) and promoted the development of
hepatocellular carcinoma (Moriya et al., 1998). The ability of
Core protein to mimic HCV disease in the mousemodel suggests
that theexpressionof thisprotein is integral toHCVpathogenesis.
To investigate the molecular mechanisms of the HCV Core
protein induced changes in hepatocytes, we examined the gene
expression profiles of HepG2 hepatocytes in the presence of
HCV Core protein by DNA microarray analysis. Our data
showed that HCV Core protein expression led to modulation of
genes regulating immune defense response, anti-apoptosis, and
genes previously known as markers of hepatic tumorigenesis.
The analysis of the interconnecting network of gene functions
suggests that HCV Core may interfere with the immune defense
response primarily through regulation and quenching of NFKB
activation. The alteration of NFKB function could lead to the
suppression of inflammatory responses and ensure the survival
of HCV infected hepatocytes from immune surveillance. In
addition, Core expression also altered the gene expression that
could confer protection of cells from apoptosis. Our data
suggest that HCV Core may play an important role in the
mechanism of HCV viral persistence in addition to acting as the
building blocks of the viral capsid.
Results
HCV Core protein expression led to decreased hepatocyte cell
proliferation
We investigated the effect of HCV Core protein on
hepatocyte proliferation following the induction of Core
expression in HepG2-Core hepatocyte cells. We used an
ecdysone-inducible expression system (Materials and methodssection) to achieve inducible expression of HCV Core protein in
HepG2 hepatocytes. This system allowed us to examine
alterations in hepatocyte proliferation and gene expression
immediately following the induction of Core protein expres-
sion. The advantage of the inducible expression systems is that
it prevents any modification of the normal cell phenotype that is
associated with exposure to high constitutive expression of Core
protein in the cells. We also appended to the N-terminus of HCV
Core protein with a sensitive 3XFLAG peptide tag to enhance
the sensitivity of detection of HCV Core expression. As shown
by Western blot analysis using anti-FLAG antibodies (Fig. 1A),
HCV Core protein was expressed in hepatocytes induced by
ponasterone A (PonA), a synthetic analog of insect ecdysone,
but not in uninduced HepG2 cells. The numbers in the
parentheses indicate the subsets of the triplicate experiment.
The exaggerated intensity of Core protein expression shown in
the figure is due to the sensitivity of the 3XFLAG tag. We have
previously shown that the level of Core protein in our
expression system was significantly less pronounced when we
used anti-Core antibody to directly detect Core protein
expression (Nguyen et al., 2003). There was no visual
indication of significant cytotoxicity or cell death in HepG2
cells following the induction of Core protein expression, as
indicated by the normal morphology of the cells in the cultures
and the lack of cellular uptake of the Trypan Blue dye, an
Fig. 2. Graphical hierarchical clustering pattern demonstrated gene expression
induced by HCV Core protein in HepG2 cells. The 3 columns on the left
represent the mRNA expression profiles of HepG2-Core-expressing cells, and
the 3 right columns represent expression profiles of HepG2 control cells
(blue = low expression, red = high expression). The graphical cluster was
generated using the dChip array analysis program.
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cytotoxicity in mock-induced control HepG2 cells following the
addition of PonA. The expression of Core protein for 48 h in
induced HepG2-Core cells resulted in a lower number of cell
counts as compared to uninduced HepG2-Core cell cultures
(Fig. 1B). The counted cell number was 25% less for cells
expressing Core protein compared to cells without Core protein
expression. There was no significant difference in the number of
cells counted in untreated and PonA treated HepG2 controls
(NT I vs. NT U), indicating that the lower cell number was
dependent on Core protein expression and was independent of
PonA treatment. This observation is consistent with our
previous studies, which suggested that HCV Core blocked
cell proliferation at the G1-S phase of the cell cycle (Nguyen et
al., 2003).
HCV Core protein induced changes in hepatocyte gene
expression
In order to identify genes and molecular processes associated
with Core induced changes in hepatocyte cell proliferation, we
evaluated gene expression profiles of Core-expressing HepG2-
Core cells in comparison to PonA induced control nontrans-
fected HepG2 cells. The Core expression led to changes (1.3-
fold or more and P value of less than or equal to 0.05) in mRNA
expression of 534 genes; 453 upregulated genes, 81 down-
regulated genes. The initial screenings were conducted with
more stringent fold change standards to screen for most
prominent changes. However, the high rigid fold change
thresholds produced spotty data that omitted many smaller
changes of genes that have significant statistical confidential P
values. We included in this report genes that have small but
consistent fold changes that also accompanied with significant
confident P values. Hierarchical clustering graph of the
significant gene list showed a distinct expression pattern
associated with HCV Core protein expression (Fig. 2). GO
Ontological classification of this list of genes showed that Core
protein expression led to a modulation of genes involved in the
regulation of immune response as well as apoptosis (Tables 1,
2). These genes and their respective biological functions and
processes were further analyzed to determine the possible
effects from their altered expression.
HCV Core expression modulates immune response genes
The expression of Core protein in HepG2 cells resulted in the
modulation of genes regulating host immune responses to
pathogens (Table 1). The altered expression pattern of immune
response genes indicated that the Core protein may dampen the
effectiveness of the immune response to HCV infection. HCV
Core led to an increased expression of some genes involved in
innate immunity. Genes with increased expression included
MHC class I polypeptide-related sequence B (MICB), NK cell
transcript 4 (NK4/IL-32), defensin beta 1 (DEFB1), beta-2-
microglobulin (B2M) and nuclear factor of kappa inhibitor light
alpha (NFKBIA/IKBα). MICB is a ligand of NKG2D type II
receptor that can activate the cytolytic response of natural killer(NK) cells, CD8 αβ T cells, and γδ T cells (Groh et al., 1998).
NK4 was initially discovered as a product of IL-2 activated NK
cells (Dahl et al., 1992), and it is recently suggested to induce
inflammatory factors, and it is also an antagonist to HGF
induced cell growth and an inhibitor of angiogenesis (Matsu-
moto and Nakamura, 2003). Defensin B1 is a member of the
microbactericidal peptide family that plays an important role in
innate immune response at mucosal surfaces. Defensin B1 has
been shown to be expressed and readily detectable in
hepatocytes, and the presence of Defensin B1 in hepatic tissues
was proposed to act as defense mechanism against pathogenic
infection of the hepatic biliary system (Harada et al., 2004).
B2M has a close homology to the immunoglobulins, and its
expression is essential for the expression and assembly of HLA
class I (Arce-Gomez et al., 1978; D'Urso et al., 1991). The
NFKBIA (IKBα) protein has a crucial role in regulating
immune response, inflammation and apoptosis since it is the
main regulator of NFKB activation (Viatour et al., 2005). The
increased expression of IKBα could result in a widespread
dysregulation of NFKB transactivated genes. The pro-inflam-
matory genes downstream of NFKB activation could be
suppressed due to the enhanced expression of IKBα by HCV
Core.
The expression of HCV Core expression also resulted in the
downregulation of tumor necrosis factor (ligand) superfamily,
member 10 (TNFSF10/TRAIL), liver activation regulated
chemokine (LARC/CCL20/MIP3A), secreted phosphoprotein
Table 1
Immune response related genes were modulated by HCV Core expression
Gene name and probe set Fold
change
P value
LARC/MIP3A/CCL20 (liver activation regulated
chemokine, 205476_AT)
−3.15 0.00108
SSP1/Osteopontin (secreted phosphoprotein 1,
209875_S_AT)
−3.04 0.00374
TNFSF10 (tumor necrosis factor (ligand) superfamily,
member 10, 202688_AT)
−1.89 0.01131
IL1RL1LG/ST2L (interleukin 1 receptor-like 1 ligand,
203679_AT)
−1.54 0.03166
FN1 (fibronectin 1, 212464_S_AT) −1.45 0.01966
MAP2K3 (mitogen-activated protein kinase kinase 3,
215499_AT)
1.36 0.03018
B2M (Beta-2-microglobulin, 201891_S_AT) 1.42 0.01596
CTSC (cathepsin C, 201487_AT) 1.42 0.00750
MICB (MHC class I polypeptide-related sequence B,
206247_AT)
1.56 0.01557
NK4 (NK cell transcript 4, 203828_S_AT) 1.63 0.01613
PLA2G2A (phospholipase A2, group IIA, 203649_s_at) 1.76 0.00007
Nuclear factor of kappa inhibitor light alpha (NFKBIA,
201502_s_at)
1.90 0.00040
DEFB1 (defensin, beta 1, 210397_AT) 3.04 0.00449
Table 2
Genes regulating apoptosis were modulated by HCV core expression
Gene name and probe set Fold
change
P
value
Tax1 (human T cell leukemia virus type I) binding protein 1
(TAX1BP1, 200976_s_at)
1.34 0.032
BAX inhibitor 1/Testis enhanced gene transcript (BI1,
200803_s_at)
1.36 0.0016
Apoptosis inhibitor 5 (API5, 201687_s_at) 1.49 0.0358
Death-associated protein 6 (DAXX, 201763_s_at) 1.55 0.0387
Tumor necrosis factor, alpha-induced protein 3 (A20,
202644_s_at)
1.65 0.0115
p21 (CDKN1A)-activated kinase 2 (PAK2, 208877_at) 1.79 0.0119
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(PLA2G2A). TNFSF10 is a member of the TNF family of
proteins that function as strong mediators of immune regulation
and the inflammatory response. The presence of TNFSF10 was
demonstrated in liver tissues of HCV infected patients and
cultured hepatocytes (Mundt et al., 2003). TNFSF10 was shown
to act through the TRAIL pathway to induce apoptosis on
diverse tumor cell lines (Wiley et al., 1995). PLA2G2A is best
known as the inflammatory factor that is highly expressed in
synovial fluid of arthritic joints, and its downregulation in the
present of HCV Core expression is interesting from the
perspective of its role in the pro-inflammatory process. LARC
and osteopontin function as chemo-attractants for recruitment of
CD4+, CD8+, and CD44+ T lymphocytes (Homey et al., 2000;
Nelson et al., 2001; Weber et al., 1996). As the functions of the
gene products were briefly outlined above, the data suggest that
the expression of HCV Core could hamper the recruitment of
immune cells by inhibiting the expression pattern of immune
and chemokine factors.
HCV Core induced anti-apoptosis factors
Expression of HCV Core protein in hepatocytes led to
enhanced expression of genes with anti-apoptotic functions.
This gene category included p21-activated protein kinase
(PAK)-2, apoptosis inhibitor 5 (API5), BAX inhibitor 1
(BH1), Tax1 (human T-cell leukemia virus type I) binding
protein 1 (Tax1BP1), death-associated protein 6 (DAXX), and
tumor necrosis factor-alpha-induced protein 3 (TNFAIP3/A20)
(Table 2).
PAK-2 is a gamma protein member of the PAK family that is
phosphorylated by the p21 CdKI. PAK2 participates in multiple
cellular processes that include acting as a substrate for caspase 3
cleavage during the apoptotic process (Chan et al., 1998).However, the expression of full-length PAK-2 was shown to
protect NIH-3T3 mouse fibroblast cell line against apoptosis
stimulated by TNF-α or growth factor removal or UV light by
preventing the pro-apoptosis Bad protein from dimerization
with Bcl2 (Jakobi et al., 2001). The API5 factor is another anti-
apoptosis factor whose expression was increased in the presence
of HCV Core protein. The API5 was shown to protect NIH-3T3
and human cervical cell lines from undergoing apoptosis
following serum starvation (Kim et al., 2000; Tewari et al.,
1997). The expression of BI1 was also increased with the
expression of Core. The BI1 is a known anti-apoptosis factor
that can block Bax induced apoptosis (Xu and Reed, 1998). Our
data showed that the expression of Tax1BP1/T6BP and
TNFAIP3/A20 genes was also increased in the presence of
HCV Core. Together, Tax1BP1 and A20 form a protein
complex that effectively blocks TNF-α induced apoptosis of
3T3 cells (De Valck et al., 1999). An increased expression of
DAXX was also observed in Core-expressing HepG2 cells. The
effect of DAXX expression on apoptosis has not been well
defined. DAXX was shown to enhance Fas mediated apoptosis
(Pluta et al., 1998; Yang et al., 1997), however, RNAi silencing
of DAXX was shown to sensitize cells to apoptosis (Chen and
Chen, 2003; Michaelson and Leder, 2003).
The data of showed that HCV Core expression correlated
with the increased expression of factors known to protect cells
against apoptosis. Interestingly, both Tax1BP1/T6BP and A20
were shown to inhibit activation of NFKB and downstream
transactivation inflammatory responses (Heyninck et al., 1999;
Iha et al., 2000). DAXX was also reported to repress NFKB
activation and expression (Michaelson and Leder, 2003).
Expression of known tumor markers
The HCV Core protein induced expression of genes
previously known to be the markers of various human tumors.
Increased levels of Ep-CAM, S100A6, IGF-2, Kras2, and
Cyclin D1 were found in Core-expressing hepatocytes (Table
3). The transmembrane glycoprotein Ep-CAM is expressed in
normal epithelium of different tissues. Overexpression of this
gene has been documented in a variety of human carcinomas
(Went et al., 2004) and is considered as a marker associated with
the development of HCC (Ruck et al., 2000). DNA microarray
analysis showed that the expression of Ep-CAM increased in
tissues of individuals identified to be at high risk to develop
Table 4
RT-PCR validation of DNA microarray data
Gene name Fold change (HepG2-Core induced vs. HepG2 induced)
GAPDH normalized 18S normalized Microarray value
CCL20/MIP3A −2.56 −1.61 −3.15
IGF2 1.62 2.58 3.49
KRAS2 2.93 4.66 7.50
PCNA 2.17 3.46 1.89
Table 3
Tumor marker genes were modulated by HCV Core expression
Gene name and probe set Fold
change
P value
IGF2 (insulin-like growth factor 2/Somatomedin A,
202410_X_AT)
3.49 0.00006
CCND1 (cyclin D1, 208711_S_AT) 2.71 0.00483
Ep-CAM/TACSTD1 (tumor-associated calcium signal
transducer 1, 201839_S_AT)
1.47 0.04533
S100A6 (S100 calcium binding protein A6, 217728_AT) 1.46 0.00848
KRAS2 (v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene
homolog, 214352_S_AT)
7.5 0.00414
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calcium-binding protein family that has been linked with cancer
tumorigenesis and metastasis. S100A6 was highly expressed in
the metastasizing fronts of colorectal adenocarcinomas and liver
metastases (Cross et al., 2005; Komatsu et al., 2002). IGF2 is a
secreted factor that appears to be an autocrine regulator of cell
proliferation (Lund et al., 2004). Increased expression of IGF2
was reported in HCC samples compared to normal liver samples
(Xu et al., 2001). IGF2 expression levels were also found to be
elevated in Wilms tumor tissues (Scott et al., 1985). The loss of
paternal imprinting of IGF2 is a potential correlate of colorectal
cancer development (Cui et al., 2003). The loss of imprint of
IGF-2 has also been suggested to contribute to the progression
of HCC (Iizuka et al., 2004; Tannapfel et al., 2003). KRAS2 is a
GTPase that transduces signal from cell surface receptors. The
activation of Kras2 either due to mutations or by increased
expression has been shown to be a corollary of various forms of
cancer. Cyclin D1 has been implicated in cell transformation,
and its expression was altered in cirrhotic and HCC tissues
(Smith et al., 2003; Xu et al., 2001). Cyclin D1 expression
contributed to rat kidney cell transformation by complementing
a defective adenovirus E1A oncogene (Hinds et al., 1994). The
data indicated that HCV Core expression resulted in the
enhanced expression of genes that are markers of tumors
including hepatic tumor.
Validation of DNA microarray data by real-time RT-PCR and
Western blotting
We utilized Real time RT-PCR to measure the transcript
levels of selected genes to validate the changes in gene
expression observed by DNA microarray analysis. Expression
levels of LARC/CCL20, IGF2, Kras2, and PCNA were
quantitated using 18S ribosomal and GAPDH genes as the
internal controls. These genes were selected for validation as
they represented a diverse magnitude of changes and intensity
of expression as seen from the DNA microarray data. The
increase or decrease in expression of these genes by DNA
microarray analysis was in general agreement with the real-time
RT-PCR validation data (Table 4). Table 4 shows the data for
induced HepG2-Core and induced nontransfected HepG2 cell
lines to validate the numbers obtained from our DNA
microarray data. We also determined the changes in the gene
expression between the PonA induced and noninduced cellcultures to compensate for differences due to the presence of
PonA. A minimal change in gene expression levels between the
PonA induced and noninduced cells was observed. This slightly
affected the numerical fold change values between induced
HepG2-Core and induced nontransfected HepG2 samples, but
the compensated values did not alter the direction of change
(data not shown).
The DNA microarray data showed that proliferating cell
nuclear antigen (PCNA) mRNA was upregulated in HepG2
cells with HCV Core expression. PCNA is an important
component of the DNA polymerase complex that is essential for
the DNA synthesis process that occurs during cell division and
proliferation (Bowman et al., 2004). PCNA is also known to
interact with p21 and act as a component of the RAD6-
dependent DNA repair mechanism (Hoege et al., 2002). It is
possible that the arrest of cells at the G0/G1 and the increase of
p21 levels could cause the initiation of PCNA transcription to
activate the DNA damage and repair surveillance mechanisms.
Other studies utilizing DNA microarrays also reported an
increased expression of PCNA in HCV infected liver samples
(Smith et al., 2003; Zindy et al., 2005). Western blot analysis of
PCNA expression was performed to correlate changes observed
at the mRNA level to the changes at the protein level. The levels
of PCNA protein in induced (I) cells expressing HCV Core
protein (Fig. 3, lanes 3 and 6) were found to be higher than in
nontransfected (NT, lanes 1 and 4) and uninduced (UI, lanes 2
and 5) cells without HCV Core expression. The addition of
PonA to HepG2 cells did not alter PCNA protein levels (lanes 1
vs. 2 and 4 vs. 5). Each lane was loaded with equal amounts of
proteins as shown by the GAPDH levels. The change of PCNA
protein level is small but consistent with the change of PCNA
mRNA expression in HCV Core-expressing cells. Additional
Western blots were conducted to verify the protein levels for
IKBα and PAK2. The direction of changes of protein levels of
IKBα and PAK2 also reflected the direction of changes of their
mRNA.
Discussion
In this study, the DNA microarray analysis of HCV Core
protein expressing HepG2 cells provided additional information
to changes that have been detected in the HepG2 cell line gene
expression profile induced by HCV-1b Core protein. The
expression data suggested that HCV Core expression led to the
decrease of cell proliferation, repression of pro-inflammatory
signals, and enhanced expression of anti-apoptosis factors. This
could lead to prevention of host cell death from apoptosis and
Fig. 3. Western blot analysis of PCNA, IKBα and PAK2 protein levels in HCV
Core-expressing hepatocytes. PCNA, IKBα and PAK2 protein levels were
detected in HepG2-Core induced (I) cells (lanes 3 and 6) and HepG2-Core
uninduced (UI) cells (lanes 2 and 5) and nontransfected (NT) HepG2 induced
control cells (lane 1 and 3). The detection of the Flag-tagged HCV Core protein
is shown on the top panel. The levels of GAPDH are shown to demonstrate the
amount of protein loaded in each lane. The same membrane blot was used to
probe for each protein, the membrane was sectioned and probed (or re-probed)
with different antibodies to ensure consistency.
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gene functions and regulators suggested that the regulation of
NFKB might be a central target for HCV Core in its attempts to
modulate apoptosis and immune suppression in hepatocytes. In
addition, HCV Core affected the expression of other cellular
factors that may result in the alteration of cell growth
characteristics. It is unlikely that inhibitions in downstream
translational processes would nullify the interpretation of the
transcriptional data since, in the HepG2 cell expression system,
it was shown that HCV Core expression did not affect cap-
dependent translation (Li et al., 2003; Shimoike et al., 2006).
Furthermore, cap-dependent translation was not affected by
varying the amount of HCV Core in the in vitro translation
system (Boni et al., 2005).
The gene expression data from this study provide support to
the hypothesis that HCV Core expression decreases cell
proliferation. We observed an increased of Geminin and
KHDRBS1 (1.5- and 1.57-fold increase). These genes were of
special interest due to their anti-proliferative functions that
could potentially contribute to the observed slower proliferation
of Core-expressing cells. The increased expression of Geminin
has been shown to inhibit DNA replication during S, G2, and M
phases by preventing complete assembly of the DNA pre-
replication complex (McGarry and Kirschner, 1998).
KHDRBS1 is a tyrosine-phosphorylated, Src-associated protein
in mitotic cells. KHDRBS1 expression was demonstrated to
inhibit serum-induced DNA synthesis, suggesting that it may
play a role in controlling the G1/S cell cycle transition (Barlat et
al., 1997). In addition, the decreased expression of LARC,
hepatocyte growth factor receptor (HGRF/met, 1.34-folddecrease), and alpha fetal protein (AFP, 2.64-fold decrease)
was observed. LARC functions primarily as a chemotaxis
factor, it can act as an autocrine/paracrine factor that enhances
hepatic cell growth (Fujii et al., 2004). The suppression of
LARC expression correlated with decreased proliferation of
HCV Core-expressing cells. The decreased expression of two
hepatic pro-growth factors, HGFR and AFP in HepG2 cells
expressing Core protein also are supportive of the observation
that HCV Core protein expression suppresses cell proliferation.
Decreased expression of HGFR could reduce the number of
receptors that are available to receive and transmit growth
signals. It is thought that an increased serum AFP level is
prognostic of active liver regeneration (Karvountzis and
Redeker, 1974), and conversely a decrease in AFP transcription
could be interpreted as an indicator of lower hepatocyte
regeneration and proliferation.
Overall, the change (increased or decreased) in the
expression of immune response-associated genes in the Core-
expressing hepatocytes seemed to have the potential to
negatively impact the anti-viral immune response. The gene
expression data suggested that HCV Core may impair
inflammatory responses and enhance cell survival of infected
cells by interfering with trafficking and infiltration of immune
cells to the site of HCV infection and by preventing cell death
from necrosis and apoptosis. Downmodulation of the expres-
sion of chemotactic factors such as LARC, and osteopontin
could suppress immune cell trafficking. LARC is the known
chemotactic ligand for the CCR6 receptor on B cells, T cells,
dendritic cells, and macrophages. The presence of LARC
expression is correlated to the increased necrosis levels of
inflamed liver tissue (Shimizu et al., 2001). Previous studies
showed the levels of LARC increased in HCV patients that
responded to INF treatment as compared to no change in the
levels of LARC in patients that were classified as nonresponders
(Yamauchi et al., 2002). These findings suggested that LARC
plays an important role of recruiting immune cells for the
effective mediation of inflammatory response and clearance of
viral infection. In this context, HCV Core could impair an
effective inflammatory response and prevent viral clearance by
repressing the expression of LARC. Our data also showed that
HCV Core suppressed osteopontin expression which is
consistent with a previous report (Ohkawa et al., 2003). The
secretion of the extracellular matrix protein osteopontin by NK
cells recruits and activates neutrophils and macrophages (Diao
et al., 2004; Weber et al., 2002). The correlation between high
osteopontin levels and hepatic tissue injury due to the increase
of neutrophil infiltration was demonstrated in the rat model
(Apte et al., 2005). The inverse relationship between LARC,
osteopontin levels, and HCV Core expression suggests a
possible mechanism of immune evasion employed by the
Hepatitis C virus.
HCV Core could contribute to viral persistence by regulating
anti-apoptosis factors that could prevents apoptosis and enhance
the survival of HCV infected host cells. The upregulation of
predominantly anti-apoptosis genes such as PAK2, API5, BH1,
Tax1BP1, TNFAIP3/A20, and DAXX demonstrated the
potential anti-apoptotic property of HCV Core. An enhanced
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inhibit stress-induced apoptosis in various cell lines (De Valck
et al., 1999; Kim et al., 2000; Tewari et al., 1997; Xu and Reed,
1998). The functions of some of these anti-apoptosis genes are
conserved across a wide spectrum of organisms. For example,
the plant homologous of BI1 was shown to suppress Bax
induced apoptosis in yeast (Kawai et al., 1999; Sanchez et al.,
2000; Xu and Reed, 1998). The normal expression of BI1 and
DAXX is required for different cell lines to avoid spontaneous
apoptosis (Grzmil et al., 2003; Kawai et al., 1999; Sanchez et
al., 2000; Xu and Reed, 1998). The modulation of TNFSF10,
API5, A20/TNFAIP3 by HCV Core was also recently shown by
2-color DNA microarrays (Liu et al., 2005). It was proposed
that the TNFSF10 ligand/receptor system is a hepatic paracrine
mechanism to eliminate virally infected hepatocytes (Mundt et
al., 2003). Suppression of TNFSF10 expression by HCV Core
may minimize apoptosis of infected host cells and maintain
HCV persistence which suggests an additional anti-apoptosis
mechanism employed by HCV Core to prevent viral clearance.
These data suggest that HCV Core expression could contribute
to the prevention of apoptosis by altering the expression of
important the anti-apoptosis factors.
The NFKB is a major transcription factor that is involved in
the activation of inflammatory and cell activation factors. The
suppression of NFKB activation by HCV Core protein may
include multiple mechanisms. Our gene expression analysis has
identified a number of genes that could contribute to the
mechanisms of inflammatory repression at the molecular level.
Recent reports linked HCV Core protein to the inactivation of
NFKB (Joo et al., 2005; Ray et al., 2002). Anti-apoptosis genes
(DAXX, Tax1BP1, A20) and immune response genes
(PLA2G2A, NFKBIA/IkBa) have been previously demonstrat-
ed to regulate the activity of NFKB. Using NFKB reporter
constructs, it was shown that increased expression of DAXX
caused the repression of the NFKB promoter (Michaelson and
Leder, 2003). Similarly, overexpression of TaxBP1 led to
suppression of the NFKB promoter (Iha et al., 2000). The A20
protein directly interacts with Tax1BP1, and exerts anti-
apoptosis effects (De Valck et al., 1999). The A20 protein
was a crucial anti-apoptotic factor in the mouse model and that
A20-deficient mice were susceptible to sub-lethal doses of TNF
(Lee et al., 2000). The A20 protein was shown to block IL-1
and TNF activation of NFKB via its interaction with TNF
receptor associated factor 2 (TRAF2) and TRAF6 (Heyninck
and Beyaert, 1999; Heyninck et al., 1999) and consequently
ensure the cytoplasmic sequestration and inactivation of NFKB
by the IkB complex. The function of PLA2G2A protein in
inflammation is through its enzymatic activity to release
arachidonic acid from cellular phospholipids. Arachidonic acid
is the precursor of prostaglandins and leukotrienes. Prosta-
glandins are vasodilators and chemotaxis factors that promote
neutrophil migration and accumulation at the sites of
inflammation. PLA2G2A induced production of the monocyte
chemotactic protein-1 (MCP-1) chemoattractant (Fuentes et al.,
2002) in macrophages. The injection of PLA2G2A has been
shown to exacerbate the inflammation of arthritic joints
(Bomalaski et al., 1991). Following the stimulation of aRAW264.7 macrophage cell line with PLA2G2A, an enhanced
binding of NFKB to its promoter sequences and degradation of
the IkBa subunit was reported (Baek et al., 2001). Lastly, HCV
Core expression led to increased expression of IkBa subunit of
the IkB complex. The increased presence of IkB complexes
would enhance sequestration and inactivation of the NFKB
transcription complex. Our gene expression data provided
novel findings that suggest that the expression of genes
regulating NFKB was altered to suppress NFKB activation and
subsequently would decrease inflammation. Furthermore, the
direction of changes for anti-apoptosis, chemotaxis, and
inflammation genes support the hypothesis that the Core
protein could contribute to the immunosuppressive nature of
the HCV.
HCV Core protein was suggested to have an immunosup-
pressive effect through the downregulation of Cox-2 gene
expression (Jhaveri et al., 2005), which might be a result of
NFKB inactivation (Joo et al., 2005). Most recently, HCV Core
was shown to inhibit T cell function and chemokine production
through the interaction with complement receptor gC1qR (Yao
et al., 2005). The HCV Core protein expression also led to down
modulation of a number of immunity and inflammatory
response related genes in Huh-7 cell line (Fukutomi et al.,
2005). The DNA microarray analysis in the chimpanzee model
of HCV infection showed that the control and clearance of HCV
infection was related to the intrahepatic infiltration of immune
cells where as chronic infections correlated with impaired gene
expression for T cell recruitment (Su et al., 2002; Thimme et al.,
2002). Expression of immune response related genes was
downmodulated in liver during chronic HCV infection in
humans and chimpanzees (Bigger et al., 2004; Honda et al.,
2001; Shao et al., 2005). The mechanisms could include the
block in the maturation process of T cells (Bigger et al., 2004)
and an enhanced expression of anti-inflammatory genes (Honda
et al., 2001). HCV has also been shown to infect and replicate in
lymph nodes, PBMC, monocyte/macrophages (Caussin-
Schwemling et al., 2001; Laskus et al., 1998), which could
also affect immune functions.
In summary, we investigated the effect of HCV Core on
hepatocyte cell proliferation and gene expression. Our results
showed that the Core protein expression led to the suppression
of chemotaxis and inflammatory factors and enhanced the
expression of anti-apoptosis factors that could lead to the
protection of infected hepatocytes from immune clearance and
apoptosis. Thus, HCV Core protein may play an important role
in the survival and persistence of Hepatitis C virus in infected
hepatocytes.
Materials and methods
Cell culture
HepG2 cells were obtained from American Type Culture
Collection (Manassas, VA.). Cells were maintained in DMEM
growth media supplemented with 10% fetal bovine serum,
2 mM L-glutamine, and 100 U of penicillin-streptomycin/ml
(GIBCO-BRL, Rockville, Md.).
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inducible Core expression
The establishment of a HepG2 cell line with the ecdysone
inducible expression of HCV Core (HCV-1b) expression was
previously described (Nguyen et al., 2003). Briefly, the
ecdysone inducible system consists of an inducible pIND
expression plasmid and an inducer pVgRxR. The inducible
plasmid pIND-Core was generated by cloning the sequence of
the FLAG-tagged Core into ecdysone-inducible mammalian
expression vector pIND (Invitrogen, Carlsbad, CA) containing
a neomycin (G418) selection marker. The expression of Core is
under the control of Drosophila melanogaster minimal heat
shock promoter and the ecdysone and glucocorticoid response
element (E/GRE) hybrid promoter. The E/GRE promoter is
driven the RxR and VgEcR ecdysone receptor subunits that are
encoded and constitutively expressed by the pVgRxR plasmid
(Invitrogen). The pVgRxR plasmid also contains a Zeocin
selection marker for the generation of stable Zeocin-resistant
cell clones. The binding of the RxR and VgEcR subunits to the
E/GRE promoter is facilitated by the addition of ponasterone A
(PonA).
HepG2 cells were co-transfected with linearized pIND-
3XFLAG-Core and pVgRxR plasmids by electroporation of
5 × 106 cells in 0.5 ml of growth media without serum at 250 V
and 950 μF using a Gene Pulser (Bio-Rad, Hercules, CA) and
incubated overnight. The transfected cells were expanded in
selection media containing 1000 μg/ml of G418 and 200 μg/ml
of Zeocin for 2 weeks. The cell colonies were transferred into
24-well plates and maintained in the G418/Zeocin selection
media for 2 to 3 weeks. Cell clones that survived the second
round of selection were expanded and evaluated for HCV Core
expression by Western blots.
Hepatocyte growth conditions and collection
HepG2-Core cells and nontransfected (NT) control cell line
were grown in tissue culture plates for mRNA and protein
extraction. PonA was used to induce expression of HCV Core
protein in the cells (10 μM). PonAwas also added to NT cells to
serve as parallel controls. Four cell growth conditions were as
following: (i) HepG2-Core cells with induction using PonA, (ii)
HepG2-Core cells without induction, (iii) untransfected control
HepG2 cells with PonA addition, (iv) untransfected control
HepG2 cells without PonA addition. Assay was performed in
triplicates. Cells were collected and were immediately frozen.
Total RNAwas isolated from HepG2-Core cells with induction
of Core expression (Core I), uninduced HepG2-Core cells (Core
U), induced NT control HepG2 cells (NT I), uninduced NT
control HepG2 (NT U) and used in the DNA microarray
analysis and Real time RT-PCR (TaqMan) assay.
Cell viability and enumeration with Trypan blue
HepG2-Core (Core) and HepG2 control (NT) cells were
trypsinized to single cell suspensions and were counted to
enumerate cell density. Equal number of cells (5 × 105) wereseeded in each well of the 6-well plates. Cells were grown
overnight and subjected to PonA administration. Cells were
harvested 48 h following induction and suspended in 1 ml of
media after trypsinization with 0.5 ml of trypsin. Each cell
suspension was mixed with equal volume of Trypan Blue dye
(25 μl/25 μl) to detect viable cells. The Trypan Blue
suspensions were spotted on a hemacytometer and live cell
numbers (without Trypan blue uptake) were counted per each
sample using a light microscope. For the measurement of cell
growth for each set of experiments performed in triplicates, cell
numbers of Core uninduced and NT uninduced cell samples
were considered to be 100% and were used as controls. The
numbers of cells from each Core I and NT I cell samples were
compared with the controls and growth percentage values for
Core I and NT I cells were derived.
DNA microarray analysis
The human HG-U133A GeneChips were used for the gene
expression profiling (Affymetrix, Santa Clara, CA, USA). RNA
extraction, amplification, labeling, hybridization, staining, and
scanning were performed as per recommendations (Affymetrix
Technical Manual). Fluorescence intensity values (.CEL files)
generated from hybridized, stained GeneChips were subjected
to comparative and hierarchical clustering analyses using the
dChip (Version 1.3) software program (Li and Wong, Harvard
University). The detection P value of 0.05 or better was used as
a statistical criterion for including a given gene in subsequent
comparative or clustering analyses. A P value of 0.05 or less
was used as a cutoff for identification of significant gene
clusters. The initial hierarchical clustering was generated from
the list of gene transcripts that were either upregulated or
downregulated at least 1.5-fold from comparisons between
experimental and control samples. We used D-chip's Gene
Ontology (GO) classification feature to group genes into
functional categories. We also re-examined the data to include
genes with 1.3-fold change (P value < 0.05) that could provide
additional pertinent information.
Immunoblot analysis
HepG2 cells were lysed in NP-40 lysis buffer and 30 μg of
total protein was separated on SDS-PAGE gels and transferred
to BA-85 membrane (Schleicher and Schuell, Keene, NH). The
membrane was stained with Ponceau S to detect protein. It was
reacted with 5% nonfat dry milk in phosphate buffered saline
(PBS) and 0.1% Tween for 1 hour before the addition of specific
primary antibodies to eliminate nonspecific binding. FLAG-
tagged HCV Core, PCNA, GAPDH, IKBα, and PAK2 proteins
were detected using anti FLAG antibody (Stratagene. La Jolla,
CA), anti-PCNA and anti-GAPDH antibodies (Santa Cruz
Biotech. Santa Cruz, CA), anti- IKBα and anti-PAK2 antibodies
(Cell Signaling Technology. Beverly, MA). After washing and
incubation with secondary mouse monoclonal or rabbit
polyclonal horseradish-peroxidase linked antibodies (Amer-
sham Pharmacia, Piscataway, NJ), proteins were detected using
ECL (Amersham Pharmacia). The same membrane blot was
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particular molecular weight ranges and probed (or re-probed)
with different antibodies to ensure consistency.
Real-time PCR
Total RNA was used to synthesize cDNA by reverse
transcription (Alluwaimi et al., 2003). Complementary DNA
was synthesized using random hexamer primers, and reactions
were carried out using PCR master mix (Applied Biosystems,
Foster City, CA). The primer probe sets for chemokine (C-C
motif) ligand 20 (CCL20), insulin-like growth factor 2 (IGF-2),
Kirsten-ras2 (Kras2), proliferating cell nuclear antigen (PCNA),
glyseraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S
ribosome were used for quantitation by real-time RT-PCR assay
(Beckton Dickinson). The house keeping genes GAPDH and
18S ribosome were used as internal controls for normalization.
Each PCR reaction was set up according to manufacturer
specificity (TaqMan Universal PCR Mastermix; Applied
Biosystems). The reactions were placed in 96-well plates and
amplified in an automated fluorometer (ABI PRISM 7700
Sequence Detection System; Applied Biosystems). Amplifica-
tion conditions included 2 min at 50 °C, 10 min at 95 °C, 40
cycles of 15 s at 95 °C, and 60 s at 60 °C. For each gene, a cycle
threshold (Ct) value was obtained at the cycle that produced a
detectable fluorescence signal. The relative Ct value of each of
the candidate gene (in reference to the control gene, i.e., CCL20
to GAPDH) was obtained by subtracting the Ct value of the
GAPDH or 18S ribosome gene from the Ct value of each
candidate gene. The average relative Ct value for each gene was
calculated from the triplicates of RNA samples. The fold change
for each gene was calculated from the difference between the
average relative Ct values of the experimental and control
samples.
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